Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intervention1: Cannabidiol

Phase 1Small molecule

UUniversity of Sao Paulo

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

EmpathyNot yet recruiting

EmpathyPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Empathy

NCT06617247

Clinical

Trials by Indication[1]

Empathy1 trial

Effects of Cannabidiol on Burnout Syndrome and Empathy of Caregivers of Older Adults

Not yet recruiting·UUniversity of Sao Paulo·Phase 1·NCT06617247·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intervention1: Cannabidiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intervention1: Cannabidiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intervention1: Cannabidiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Sao Paulo

Related News